Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.63 |
| ▸ | MAOB | P27338 | 3/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25231681 | 0.98 | MAOA (0.64) | MAOAMAOBCYP19A1SIGMAR1CYP2A6 | |
| SCHEMBL8971462 | 0.94 | MAOB (0.61) | MAOAMAOBCYP19A1SIGMAR1CYP3A4 | |
| SCHEMBL26081845 | 0.92 | MAOB (0.59) | MAOAMAOBCYP19A1SIGMAR1CYP3A4 | |
| SCHEMBL29961815 | 0.92 | MAOB (0.59) | MAOAMAOBCYP19A1SIGMAR1CYP3A4 | |
| SCHEMBL15511597 | 0.92 | MAOB (0.59) | MAOAMAOBCYP19A1SIGMAR1CYP3A4 | |
| SCHEMBL29436975 | 0.89 | MAOB (0.71) | MAOAMAOBCYP19A1SIGMAR1CYP3A4 | |
| SCHEMBL1026806 | 0.89 | MAOB (0.71) | MAOAMAOBCYP19A1SIGMAR1CYP3A4 | |
| SCHEMBL29437072 | 0.89 | MAOB (0.71) | MAOAMAOBCYP19A1SIGMAR1CYP3A4 | |
| SCHEMBL18045550 | 0.89 | MAOB (0.71) | MAOAMAOBCYP19A1SIGMAR1CYP3A4 | |
| SCHEMBL28770903 | 0.86 | MAOB (0.68) | MAOAMAOBCYP19A1SIGMAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035513-A1 | RESIN COMPOSITION, REINFORCED COMPOSITE MATERIAL, SHAPED PRODUCT, AND METHOD OF RECOVERING REINFORCING FIBER FROM REINFORCED COMPOSITE MATERIAL | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2026-02-05 | — | — | US | disclosed |
| EP-4578892-A1 | RESIN COMPOSITION, COMPOSITE REINFORCING MATERIAL, MOLDED BODY, AND METHOD FOR RECOVERING REINFORCING FIBERS FROM COMPOSITE REINFORCING MATERIAL | Asahi Kasei Kabushiki Kaisha (JP) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025127092-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学株式会社 | 2025-06-19 | — | — | WO | disclosed |
| CN-120051729-A | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display element | 日产化学株式会社 | 2025-05-27 | — | — | CN | disclosed |
| CN-119620472-A | Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element using same | 日产化学株式会社 | 2025-03-14 | — | — | CN | disclosed |
| CN-112602014-B | Method for producing liquid crystal alignment film, and liquid crystal display element | 日产化学株式会社 | 2025-02-11 | — | — | CN | disclosed |
| CN-112639595-B | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display element | 日产化学株式会社 | 2025-01-10 | — | — | CN | disclosed |
| CN-111683986-B | Composition for forming cured film, alignment material, and retardation material | 日产化学株式会社 | 2025-01-10 | — | — | CN | disclosed |
| CN-113272729-B | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display element | 日产化学株式会社 | 2024-08-20 | — | — | CN | disclosed |
| CN-113316742-B | Liquid crystal aligning agent, liquid crystal alignment film, liquid crystal display element, and novel monomer | 日产化学株式会社 | 2024-08-16 | — | — | CN | disclosed |
| WO-2010048332-A2 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-7498068-B2 | Liquid-crystal aligning agent, liquid-crystal alignment film comprising the same, and liquid-crystal element | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-7482342-B2 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2009-01-27 | — | — | US | disclosed |
| US-20070224370-A1 | Liquid-Crystal Aligning Agent, Liquid-Crystal Alignment Film Comprising the Same, and Liquid-Crystal Element | NISSAN CHEMICALS INDUSTRIES, LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| EP-1727544-A1 | USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT THAT IS INTENDED FOR THE TREATMENT AND PREVENTION OF PALUDISM | Sanofi-Aventis (FR) | 2006-12-06 | — | — | EP | disclosed |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2006-01-05 | — | — | US | disclosed |
| WO-2005099703-A1 | USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT THAT IS INTENDED FOR THE TREATMENT AND PREVENTION OF PALUDISM | SANOFI-AVENTIS (FR) | 2005-10-27 | — | — | WO | disclosed |
| EP-1549620-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | Sanofi-Aventis (FR) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031158-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | SANOFI-AVENTIS (FR) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | CYP3A43, CYP3A5, SIRT5 | MAOA 1543/4885MAOB 2017/4885CYP19A1 2568/4885 |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | CDK2, CDK1, CDK4 | MAOA 3275/4885MAOB 2982/4885CYP19A1 275/4885 |
| US-20260035513-A1 | RESIN COMPOSITION, REINFORCED COMPOSITE MATERIAL, SHAPED PRODUCT, AND METHOD OF RECOVERING REINFORCING FIBER FROM REINFORCED COMPOSITE MATERIAL | TAF1, TAF1L, TAF9 | MAOA 1110/4885MAOB 2358/4885CYP19A1 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.